File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fonc.2021.651299
- Scopus: eid_2-s2.0-85105976183
- PMID: 34012917
- WOS: WOS:000651138600001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
Title | Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer |
---|---|
Authors | |
Keywords | colorectal cancer economic evaluation decision-making economic evidence simulation models |
Issue Date | 2021 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology |
Citation | Frontiers in Oncology, 2021, v. 11, article no. 651299 How to Cite? |
Abstract | Objectives: We aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-line treatment in KRAS wild-type (WT), pan-RAS WT and pan-RAS WT left-sided metastatic colorectal cancer (mCRC) patients from the Hong Kong societal perspective.
Materials and Methods: We developed Markov models and 10-year horizon to estimate costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) of chemotherapy plus anti-EGFR therapy against chemotherapy plus Bev in KRAS WT, pan-RAS WT, and pan-RAS WT left-sided mCRC. We considered two times of the local gross domestic product per capita (GDPpc) as the willingness-to-pay (WTP) threshold (2× GDPpc; US$97,832).
Results: Adding anti-EGFR mAb to chemotherapy provides additional 0.24 (95% confidence interval [CI] 0.19–0.29), 0.32 (95% CI 0.27–0.37), and 0.57 (95% CI 0.49–0.63) QALY compared to adding Bev in KRAS WT, pan-RAS WT, and left-sided pan-RAS WT mCRC populations respectively. The corresponding ICER is US$106,847 (95% CI 87,806–134,523), US$88,565 (95% CI 75,678–105,871), US$76,537 (95% CI 67,794–87,917) per QALY gained, respectively.
Conclusions: Anti-EGFR therapy is more cost-effective than Bev as a first-line targeted therapy in left-sided pan-RAS WT and pan-RAS WT, with ICER |
Persistent Identifier | http://hdl.handle.net/10722/301938 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.066 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, SF | - |
dc.contributor.author | Choi, HCW | - |
dc.contributor.author | Chan, SK | - |
dc.contributor.author | Lam, KO | - |
dc.contributor.author | Lee, VHF | - |
dc.contributor.author | Wong, IOL | - |
dc.contributor.author | Chiang, CL | - |
dc.date.accessioned | 2021-08-21T03:29:11Z | - |
dc.date.available | 2021-08-21T03:29:11Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Frontiers in Oncology, 2021, v. 11, article no. 651299 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/10722/301938 | - |
dc.description.abstract | Objectives: We aimed to compare the economic value of chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) against chemotherapy with bevacizumab (Bev, an anti-vascular endothelial growth factor mAb) as first-line treatment in KRAS wild-type (WT), pan-RAS WT and pan-RAS WT left-sided metastatic colorectal cancer (mCRC) patients from the Hong Kong societal perspective. Materials and Methods: We developed Markov models and 10-year horizon to estimate costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) of chemotherapy plus anti-EGFR therapy against chemotherapy plus Bev in KRAS WT, pan-RAS WT, and pan-RAS WT left-sided mCRC. We considered two times of the local gross domestic product per capita (GDPpc) as the willingness-to-pay (WTP) threshold (2× GDPpc; US$97,832). Results: Adding anti-EGFR mAb to chemotherapy provides additional 0.24 (95% confidence interval [CI] 0.19–0.29), 0.32 (95% CI 0.27–0.37), and 0.57 (95% CI 0.49–0.63) QALY compared to adding Bev in KRAS WT, pan-RAS WT, and left-sided pan-RAS WT mCRC populations respectively. The corresponding ICER is US$106,847 (95% CI 87,806–134,523), US$88,565 (95% CI 75,678–105,871), US$76,537 (95% CI 67,794–87,917) per QALY gained, respectively. Conclusions: Anti-EGFR therapy is more cost-effective than Bev as a first-line targeted therapy in left-sided pan-RAS WT and pan-RAS WT, with ICER <US$100,000/QALY, compared to KRAS WT mCRC population. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology | - |
dc.relation.ispartof | Frontiers in Oncology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | colorectal cancer | - |
dc.subject | economic evaluation | - |
dc.subject | decision-making | - |
dc.subject | economic evidence | - |
dc.subject | simulation models | - |
dc.title | Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer | - |
dc.type | Article | - |
dc.identifier.email | Choi, HCW: hcchoi@hku.hk | - |
dc.identifier.email | Lam, KO: lamkaon@hku.hk | - |
dc.identifier.email | Lee, VHF: vhflee@hku.hk | - |
dc.identifier.email | Chiang, CL: chiangcl@hku.hk | - |
dc.identifier.authority | Choi, HCW=rp02815 | - |
dc.identifier.authority | Lam, KO=rp01501 | - |
dc.identifier.authority | Lee, VHF=rp00264 | - |
dc.identifier.authority | Chiang, CL=rp02241 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fonc.2021.651299 | - |
dc.identifier.pmid | 34012917 | - |
dc.identifier.pmcid | PMC8127841 | - |
dc.identifier.scopus | eid_2-s2.0-85105976183 | - |
dc.identifier.hkuros | 324221 | - |
dc.identifier.volume | 11 | - |
dc.identifier.spage | article no. 651299 | - |
dc.identifier.epage | article no. 651299 | - |
dc.identifier.isi | WOS:000651138600001 | - |
dc.publisher.place | Switzerland | - |